Related Experiment Video
Updated: Jun 11, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis
Seung-Hyun Jung1, Sung-Eun Lee2, Sujin Yun3
1Departments of Biochemistry; Departments of Precision Medicine Research Center/Integrated Research Center for Genome Polymorphism; Departments of Medical Sciences. hyun@catholic.ac.kr.
Abstract:
Primary myelofibrosis (PMF) is a myeloid proliferative neoplasm (MPN) characterized by bone marrow fibrosis. Pre-fibrotic PMF (pre-PMF) progresses to overt PMF. Megakaryocytes play a primary role in PMF; however, the functions of megakaryocyte subsets and those of other hematopoietic cells during PMF progression remain unclear. We, therefore, analyzed bone marrow aspirates in cases of pre-PMF, overt PMF, and other MPN using single-cell RNA sequencing. We identified 14 cell types with subsets, including hematopoietic stem and progenitor cells (HSPC) and megakaryocytes. HSPC in overt PMF were megakaryocyte-biased and inflammation/fibrosis-enriched. Among megakaryocytes, the epithelial-mesenchymal transition (EMT)-enriched subset was abruptly increased in overt PMF. Megakaryocytes in non-fibrotic/non-PMF MPN were megakaryocyte differentiation-enriched, whereas those in fibrotic/non-PMF MPN were inflammation/fibrosis-enriched. Overall, the inflammation/fibrosis signatures of the HSPC, megakaryocyte, and CD14+ monocyte subsets increased from pre-PMF to overt PMF. Cytotoxic and dysfunctional scores also increased in T and NK cells. Clinically, megakaryocyte and HSPC subsets with high inflammation/fibrosis signatures were frequent in the patients with peripheral blood blasts ≥1%. Single-cell RNA-sequencing predicted higher cellular communication of megakaryocyte differentiation, inflammation/fibrosis, immunological effector/dysfunction, and tumor-associated signaling in overt PMF than in pre-PMF. However, no decisive subset emerged during PMF progression. Our study demonstrated that HSPC, monocytes, and lymphoid cells contribute to the progression of PMF, and subset specificity existed regarding inflammation/fibrosis and immunological dysfunction. PMF progression may depend on alterations of multiple cell types, and EMT-enriched megakaryocytes may be potential targets for diagnosing and treating the progression.
Insights
Primary myelofibrosis (PMF) progression involves changes in hematopoietic stem and progenitor cells (HSPC) and megakaryocytes, with increased inflammation and fibrosis signatures. EMT-enriched megakaryocytes may offer diagnostic and therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Primary myelofibrosis (PMF) is a serious myeloid neoplasm characterized by bone marrow fibrosis.
- The roles of specific cell subsets, particularly megakaryocytes, in PMF progression are not fully understood.
- Understanding cellular dynamics is crucial for identifying therapeutic targets in PMF.
Purpose of the Study:
- To elucidate the functions of megakaryocyte subsets and other hematopoietic cells during PMF progression.
- To identify cellular changes associated with the transition from pre-PMF to overt PMF.
- To explore potential diagnostic and therapeutic targets based on cellular alterations.
Main Methods:
- Single-cell RNA sequencing was employed to analyze bone marrow aspirates from patients with pre-PMF, overt PMF, and other myeloproliferative neoplasms (MPN).
- Comprehensive analysis of 14 distinct cell types and their subsets, including hematopoietic stem and progenitor cells (HSPC) and megakaryocytes.
- Assessment of inflammation, fibrosis, and immunological signatures across different cell populations.
Main Results:
- Overt PMF exhibits megakaryocyte-biased and inflammation/fibrosis-enriched HSPC.
- A significant increase in epithelial-mesenchymal transition (EMT)-enriched megakaryocyte subsets was observed in overt PMF.
- Inflammation/fibrosis signatures increased in HSPC, megakocyte, and monocyte subsets from pre-PMF to overt PMF, alongside heightened cytotoxic/dysfunctional scores in T and NK cells.
Conclusions:
- PMF progression is influenced by alterations in HSPC, monocytes, and lymphoid cells, with specific subset variations in inflammation/fibrosis and immune dysfunction.
- EMT-enriched megakaryocytes represent a potential target for PMF diagnosis and treatment.
- Cellular communication analysis suggests increased signaling pathways in overt PMF compared to pre-PMF.
Related Concept Videos
Myocarditis I: Introduction
Introduction to Fibroblasts
Types of Intermediate Filaments
Myocarditis II: Clinical features and Diagnostic Tests

